Research Town Hall

April 16, 2020

Dennis Charney

Eric Nestler


Marta Filizola


Reg Miller

Roz Wright



Total research submissions are up by >10% compared with last year:





Mount Sinai has received >\$30M in new philanthropy to support COVID-19 research; and we are playing a leading role nationally and internationally:

Microbiology (Garcia-Sastre, Krammer, Marazzi, Simon, tenOever, others)

- Serologic testing
- Novel animal models
- Studies of viral infectivity and replication
- Vaccine development

Infectious Disease (Aberg, Chen, Merad, others)

 Clinical trials with antiviral agents, anti-cytokine antibodies, convalescent sera, hydroxychloroquine, many others

Immunology (Merad, Bhardwaj, Brody, Charney [Alex], Marron, Moran, Parek, others)

- Cytokine responses—adaptive and maladaptive—to infection
- Therapeutic antibodies

Continued:

Biobanking (Cordon-Cardo, Brody, Charney [Alex], Crary, Merad, others)

- Biobanking blood, sputum, lung, and many other tissues and excretions
- Biobanking autopsy specimens including brains

Genomics (Cho, Kenny, Sebra, Charney [Alex], Abul-Husn, Merad, van Bakel)

- Connecting COVID-19 infections with BioMe
- Population study of genomic determinants of COVID-19 infection
- European roots of most COVID-19 infections in NYC

Cell models (Papapetrou, Brennand, Marro, others)

human iPSC-derived cells for lung, trachea, and brain to study infectivity

PTSD Center (Kahn, Murrough, Yehuda, Charney [Dennis], Feder, Katz, Lowe, Ripp, Southwick, others)

Mount Sinai Sinai in the Time of COVID-19

Continued:

EMR, imaging, digital, and related informatic approaches (Bottinger, Fayad, Howell, Bergink, Bernheim, Charney [Alex], Darrow, Finkelstein, Freeman, Glicksberg, Glowe, Huckins, Kovatch, Levin, Nadkarni, O'Reilly, Reich, others)

- STOP COVID-19 app (more than >15,000 have signed up to date)
- NY COVID Informatics Taskforce (NYCIT)
- New insights into clinical care (e.g., use of anticoagulants)
- Outcomes for pregnant women with COVID-19 infections

Healthcare disparities (Gelijns, Horowitz, Vreeman, Bagiella, Masci, others)

Locally and globally

Bioengineering (Fayad, Friedman, others)

 NASA's Jet Propulsion Lab, with ISMMS and RPI as partners, is developing prototype ventilator

Covid Pilot Grant program to support innovative research with expected high impact within 6 months; six pilots funded to date:

- Akbarian, Stem Cell-based Approach to SARS-CoV-2 Molecular and Cellular Targets in Lung and Brain
- Bagiella, Multistate Markov Models For Covid-19 Progression, \$75,788
- Bergink, The Impact Of Sars-Cov-2 Infection During Pregnancy On Maternal And Child Outcomes
- Guccione, SSO-Mediated Induction of an Anti-SARS-CoV-2 hACE2 Decoy Receptor
- Iyengar, Identify and Repurpose Drugs to Control SARS-CoV-2 Infectivity
- Maher, COVID Viscoelastic Testing Project

Clinical trials research studies now being reviewed by a separate committee headed by Roz Wright.

Overall Research Productivity Continues

Pls, postdoctoral fellows, graduate students, and research staff are utilizing this time as productively as possible:

- WIPs, lab meetings uninterrupted
- Thesis committee meetings, thesis proposal defenses, thesis defenses ongoing
- Submitting grants
- Writing papers
- Writing review papers
- Analyzing data
- Analyzing existing datasets in new ways
- Establishing new collaborations
- Catching up with new and renewal IACUC and IRB submissions with launch of Huron (eIACUC and eIRB/Ruth)
- New seminar series (e.g., faculty WIPs)
- Department and Institute retreats held remotely
- Department workshops (e.g., DPS on Covid-19 drug discovery)

Overall Research Productivity Continues

Examples of high profile papers published or accepted in March & April alone:

Alsohime F et al (Bogunovic D, others). JAK Inhibitor Therapy in a Child with Inherited USP18 Deficiency. N Engl J Med 2020;382:256-265.

Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity 2020;in press

Baker SJ et al. (Reddy lab). A contaminant impurity and not rigosertib, is a tubulin binding agent. Mol Cell 2020;in press.

Ferland JN, Hurd YL. Deconstructing the neurobiology of cannabis use disorder. Nat Neurosci 2020;in press.

Flanigan ME et al (Russo lab). Orexin signaling in GABAergic lateral habenula neurons modulates aggressive behavior. Nat Neurosci 2020;in press.

Galsky MD et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2020;in press.

Heitman N et al (Rendl lab). Dermal sheath contraction powers stem cell niche relocation during hair cycle regression. Science 2020;367:161-166.

Humphries AC et al. (Mlodzik lab). Mutations associated with human neural tube defects display disrupted planar cell polarity in Drosophila. Elife 2020;9:e53532.

Continued:

Issler O et al (Nestler lab). Sex-specific role for the long non-coding RNA LINC00473 in depression. Neuron 2020;in press.

Lepack AE et al (Maze lab). Dopaminylation of histone H3 in ventral tegmental area regulates cocaine seeking. Science 2020;368:197-201.

Liang R et al (Ghaffari lab). Restraining Lysosomal Activity Preserves Hematopoietic Stem Cell Quiescence and Potency. Cell Stem Cell 2020;26:359-376.e7.

Maier B et al (Merad lab). A conserved dendritic-cell regulatory program limits antitumour immunity. Nature 2020;580:257-262.

Ramdhani S et al (Raj lab). Tensor decomposition of stimulated monocyte and macrophage gene expression profiles identifies neurodegenerative disease-specific trans-eQTLs. PLoS Genet 2020;16:e1008549.

Richter F et al (Gelb lab). Role of noncoding de novo variants in congenital heart disease. Nat Genet 2020; in press.

Spertus JA et al (Stone, others). Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. N Engl J Med 2020; in press.

Zhou X et al (Zou/Friedel lab). Microglia and macrophages promote corralling, wound compaction and recovery after spinal cord injury via Plexin-B2. Nat Neurosci 2020;23:337-350.

When Will We Ease Restrictions on Research Laboratories?

We need to develop a plan now that eases restrictions gradually as soon as it is safe to do so:

We will do this under the guidance of our infectious disease experts.

Wet laboratories have relatively low people densities at baseline:

Moving to staggered hours would ensure robust social distancing

What form of surveillance and containment program is needed to relaunch our laboratory efforts?

- Role for masks, PPE, more regular lab cleaning
- Role for testing

We can tentatively aim for mid-May but this will require a lot of work and depends on shifting judgements about safety (federal, state, local, institutional guidelines).

YOUR QUESTIONS